Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT)

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 1184-1195

  Rais, Rana ^a   Fletcher, Steven ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Active transport; Apical sodium dependent bile acid transporter; Bile acid; Bioavailability; Gabapentin; Permeability; Prodrugs; Stability; Transporters

Indexed keywords

APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER; BILE ACID; CARRIER PROTEIN; CHENODEOXYCHOLIC ACID; GABAPENTIN; GLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATALYSIS; CONJUGATION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENETIC TRANSFECTION; HOMOGENATE; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; RAT;

EID: 79251573235     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22332     Document Type: Article

References (24)

1. Laird MA, Gidal BE. 2000. Use of gabapentin in the treatment of neuropathic pain. Ann Pharmacother 34(6):802-807.
2. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. 1993. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10(2):276-281.
3. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H. 2002. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol 61(4):729-737.
4. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. 2000. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 40(2-3):123-127.
5. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA. 2004. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311(1):324-333.
6. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. 2004. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 311(1):315-323.
7. Richter A, Anton SE, Koch P, Dennett SL. 2003. The impact of reducing dose frequency on health outcomes. Clin Ther 25(8):2307-2335; discussion 2306.
8. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. 2008. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 48(12):1378-1388.
9. Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC. 2009. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: A randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 31(8):1776-1786.
10. Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. 2009. Gabapentin enacarbil in restless legs syndrome: A phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 32(6):311-320.
11. Madan J, Chawla G, Arora V, Malik R, Bansal AK. 2005. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 7(1):E224-230.
12. Hagenbuch B, Dawson P. 2004. The sodium bile salt cotransport family SLC10. Pflugers Arch 447(5):566-570.
13. St-Pierre MV, Kullak-Ublick GA, Hagenbuch B, Meier PJ. 2001. Transport of bile acids in hepatic and non-hepatic tissues. J Exp Biol 204(Pt 10):1673-1686.
14. Alrefai WA, Gill RK. 2007. Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm Res 24(10):1803-1823.
15. Balakrishnan A, Polli JE. 2006. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): A potential prodrug target. Mol Pharm 3(3):223-230.
16. Sievanen E. 2007. Exploitation of bile acid transport systems in prodrug design. Molecules 12(8):1859-1889.
17. Balakrishnan A, Wring SA, Coop A, Polli JE. 2006. Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol Pharm 3(3):282-292.
18. Zhang EY, Phelps MA, Cheng C, Ekins S, Swaan PW. 2002. Modeling of active transport systems. Adv Drug Deliv Rev 54(3):329-354.
19. Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. 2004. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm 1(1):40-48.
20. Balakrishnan A, Wring SA, Polli JE. 2006. Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): Influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm Res 23(7):1451-1459.
21. Gonzalez PM, Acharya C, Mackerell, AD Jr., Polli JE. 2009. Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm Res 26(7):1665-1678.
22. Balakrishnan A, Sussman DJ, Polli JE. 2005. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res 22(8):1269-U1213.
23. Balakrishnan A, Sussman DJ, Polli JE. 2005. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res 22(8):1269-1280.
24. Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. 2008. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J 10(4):596-605.